ISRCTN51896330
Completed
Not Applicable
Multicentric clinical trial on the efficacy and safety of ceftriaxone and sulbactam in lower respiratory tract infectio
Venus Remedies Limited (India)0 sites105 target enrollmentJune 23, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- ower respiratory tract infection
- Sponsor
- Venus Remedies Limited (India)
- Enrollment
- 105
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age \=18 years
- •2\. Fever \=38°C
- •3\. Sputum pus cells \>25 high power fields (HPF)
- •4\. Buccal epithelial cells \<10 HPF
Exclusion Criteria
- •1\. Hypersensitivity to ceftriaxone, sulbactam or related drugs
- •2\. Children less than 18 years of age
- •3\. Septicemic shock, active pulmonary malignancies, renal and hepatic insufficiencies
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
ACENT 1Patients with Sickle Cell Disease.Sickle cell disease (SCD) Foetal haemoglobin (HbF) mutated sickle cell haemoglobin (HbS)LBCTR2024015480ovo Nordisk87
Completed
Phase 2
Research study investigating how well NDec works in people with sickle cell disease2023-508506-22-00Novo Nordisk A/S15
Active, not recruiting
Phase 2
Research study investigating how well NDec works in people with sickle cell diseaseHealth Condition 1: D572- Sickle-cell/Hb-C diseaseCTRI/2023/01/049275ovo Nordisk AS
Active, not recruiting
Phase 1
Research study investigating how well NDec works in people with sickle cell diseaseSickle cell diseaseTherapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]CTIS2023-508506-22-00ovo Nordisk A/S87
Completed
Phase 2
The multicenter clinical trial of the efficacy and safety of bezafibrate for mitochondrial fatty acid Beta-oxidation disordersmitochondrial fatty acid Beta-oxidation disordersJPRN-UMIN000012934Shimane University School of Medicine10